BP
AXSM icon

Ballentine Partners’s Axsome Therapeutics AXSM Stock Holding History

Ballentine Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Buy
+967
New +$210K ﹤0.01% 927

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Ballentine Partners's AXSM Position: Q2 2026 in Review

Ballentine Partners opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 967 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #927 among its holdings.

52 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Ballentine Partners held 967 shares of Axsome Therapeutics worth $237K as of Q2 2026.
  • Axsome Therapeutics was a new Ballentine Partners position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #927 holding.
  • 52 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.